CVS, Aetna outline strategies to address high cost of gene therapies | Drug pricing battle heats up in Congress | Okla. lawsuit alleges oversupply by 3 opioid distributors
January 14, 2020
FOLLOW PCMA ON TWITTER Twitter
PCMA SmartBrief
News for the PBM Industry
SIGN UP ⋅   SHARE ⋅   ARCHIVE
ADVERTISEMENT
Featured Story
CVS, Aetna outline strategies to address high cost of gene therapies
A CVS Health and Aetna report outlines strategies insurers and health plan sponsors can adopt to address the costs associated with gene therapies, estimated at $14.8 billion to $45 billion over the next five years, depending on their market impact. Recommendations include relying on centers of excellence, using value-based contracting, testing financial protection programs, turning to specialty pharmacies and offering payment plans to employers.
Health Payer Intelligence (1/13),  FierceHealthcare (1/13) 
LinkedIn Twitter Facebook Email
Legislative & Regulatory News
Drug pricing battle heats up in Congress
US Senate Majority Leader Mitch McConnell, R-Ky., has been reluctant to bring legislation aimed at reducing prescription drug prices to the floor for a vote, but that could backfire as the public increasingly is demanding action to lower costs. Democratic strategists have launched an ad campaign attacking Republicans and the Trump administration for opposing a drug pricing bill sponsored by House Speaker Nancy Pelosi, D-Calif., which passed the House.
The Hill (1/10),  The Hill (1/10) 
LinkedIn Twitter Facebook Email
Okla. lawsuit alleges oversupply by 3 opioid distributors
Litigation filed by Oklahoma Attorney General Mike Hunter alleges that Cardinal Health, AmerisourceBergen and McKesson have brought an excessive supply of opioids into the state, contributing to widespread opioid abuse. The lawsuit, which seeks an unspecified amount of money for past damages, "will show that these companies poured opioids into communities across this state while ignoring red flags and suspicious orders," Hunter said.
The Oklahoman (Oklahoma City) (tiered subscription model) (1/14) 
LinkedIn Twitter Facebook Email
Drug Industry Spotlight
Novartis to provide PCSK9 inhibitor in UK on "population basis"
Novartis will offer inclisiran, a PCSK9 inhibitor acquired when Novartis bought The Medicines Co., on a "population basis" to patients in the UK who have atherosclerosis after completion of a large clinical trial and regulatory approval.
CNBC (1/13) 
LinkedIn Twitter Facebook Email
Endo pays $8.8M to settle Okla. opioid marketing lawsuit
Endo Pharmaceuticals will pay the state of Oklahoma $8.8 million to resolve allegations that its marketing practices contributed to the opioid epidemic. Most of the money will go to the state's opioid suit settlement fund.
Becker's Hospital Review (1/13) 
LinkedIn Twitter Facebook Email
  
  
Why should I deem myself to be a chisel, when I could be the artist?
J.C.F. von Schiller,
poet, philosopher, physician, historian, playwright
LinkedIn Twitter Facebook Email
  
  
Learn more about PCMA:
Upcoming PCMA Events  |    PCMA Newsroom
Become a PCMA Affiliate
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 270 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Editor  -  Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2020 SmartBrief, Inc.®
Privacy policy |  Legal Information